Biocon Q3FY26 Operating Revenue at Rs 4,173 Cr; Q3FY26 EBITDA at Rs 951 Cr; Q3FY26 Net Profit at Rs 144 Cr

  • Posted by: Biocon Biologics

Fitch Ratings Revises Biocon Biologics Outlook from ‘Stable’ to ‘Positive’

  • Posted by: Biocon Biologics

S&P Global Upgrades Biocon Biologics Credit Rating To ‘BB+’ Revises Outlook to “Stable”

  • Posted by: Biocon Biologics

Biocon Limited Concludes Rs 4,150 Crore (~USD 460 million) Equity Fundraise through a Ǫualified Institutions Placement (ǪIP)

  • Posted by: Biocon Biologics

Biocon Biologics to Expand Biosimilar Oncology Portfolio, Outline Strategic Vision at the 2026 J.P. Morgan Healthcare Conference

  • Posted by: Biocon Biologics

Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab through Expanded FKB In-Licensing Agreement

  • Posted by: Biocon Biologics

Biocon Biologics Recognized as Asia IP Elite for 2025 by IAM

  • Posted by: Biocon Biologics

Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide

  • Posted by: Biocon Biologics

S&P Global Places Biocon Biologics on Positive CreditWatch On Account of Accelerated Debt Reduction

  • Posted by: Biocon Biologics

Biocon Limited to Integrate Biocon Biologics Limited to Create a Unified Global Biopharmaceutical Leader

  • Posted by: Biocon Biologics
Share
buy twitter followers - sahadan tv - buy facebook followers -

çekişmeli boşanma avukatı

- volgers kopen - Antalya vip transfer - funbahis - tümbet - betosfer giriş - Goley90 Giriş - Casitap Giriş - Casitoros Giriş - Casino Spino Giriş